Abstract
Aim:This study aimed to evaluate the effectiveness of nutritional support guided by the PDCA cycle management model in nasopharyngeal carcinoma (NPC) patients undergoing radiotherapy.
Methods:A total of 100 NPC patients were randomly assigned to an observation group (OG) (n = 50) and a control group (CG) (n = 50). The CG received routine nutritional support, while the OG received PDCA cycle-based nutritional support. Key outcomes included blood nutritional biomarkers, quality of life (QoL), incidence of adverse reactions (ARs), and clinical efficacy.
Results: Post-treatment analysis revealed that the OG had a significantly higher total effective rate (72%) compared to the CG (38%) (P < 0.05). The OG demonstrated higher albumin, prealbumin, and total protein levels, along with lower CRP levels after treatment. Additionally, significant improvements were observed in cognitive, role, social, physical, and emotional functioning in the OG (P < 0.05). Furthermore, the AR rate was significantly lower in the OG (20%) compared to the CG (36%) (P < 0.05).
Conclusion: These findings suggest that PDCA cycle-based nutritional support improves clinical efficacy and QoL, minimizes nutritional risks and ARs, and enhances overall safety in NPC patients undergoing radiotherapy. Serum markers such as serum iron, ferritin, prealbumin, and CRP were effective in monitoring the impact of nutritional interventions on patients’ nutritional and inflammatory status.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.